(BLCO) Bausch + Lomb - Ratings and Ratios

Bausch + Lomb Corporation is a global leader in eye health, operating across the United States, Canada, China, Japan, Germany, the United Kingdom, and numerous other international markets. With a rich history dating back to its founding in 1853, the company has established itself as a key player in the ophthalmic industry, offering a diverse range of products and services that cater to various eye care needs.

The companys business is organized into three distinct segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment specializes in contact lenses, offering a broad spectrum of options to suit different wearing modalities, including daily disposable and frequently replaced lenses. Additionally, this segment provides a variety of eye care products such as over-the-counter eye drops, eye vitamins, and mineral supplements designed to address common conditions like eye allergies, conjunctivitis, dry eye, and redness relief.

The Pharmaceuticals segment focuses on developing and marketing both proprietary and generic drugs. These products are used for post-operative treatments and to treat conditions such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. This segment underscores the companys commitment to advancing eye health through innovative pharmaceutical solutions.

The Surgical segment is dedicated to providing medical devices and technologies for eye surgeries. This includes equipment and consumables for cataract, corneal, vitreous, and retinal surgeries. The segment also offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments essential for cataract surgery, highlighting the companys role in advancing surgical eye care.

Bausch + Lomb distributes its products through a combination of direct sales forces and independent distributors, ensuring a wide reach and accessibility for its customers. Notably, the company has entered into a collaboration agreement with City Therapeutics to develop a novel RNAi-Based treatment for geographic atrophy, showcasing its dedication to innovation and addressing unmet medical needs.

Headquartered in Vaughan, Canada, Bausch + Lomb operates as a subsidiary of Bausch Health Companies Inc. For more information, investors can visit their website at https://www.bausch.com.

From a financial perspective, Bausch + Lomb is listed under the ticker symbol BLCO on the Toronto Stock Exchange (TO). The company has a market capitalization of 9015.40M CAD, with a forward P/E ratio of 15.27, indicating its valuation in the market. The price-to-book (P/B) ratio stands at 0.95, and the price-to-sales (P/S) ratio is 1.92, providing insights into its financial health and investment potential.